139 related articles for article (PubMed ID: 10718947)
1. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.
Ying C; De Clercq E; Neyts J
J Viral Hepat; 2000 Jan; 7(1):79-83. PubMed ID: 10718947
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
Ying C; De Clercq E; Nicholson W; Furman P; Neyts J
J Viral Hepat; 2000 Mar; 7(2):161-5. PubMed ID: 10760047
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
6. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
8. Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions.
Buster EH; van der Eijk AA; Schalm SW
Antiviral Res; 2003 Oct; 60(2):79-85. PubMed ID: 14638402
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
10. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
[TBL] [Abstract][Full Text] [Related]
11. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
12. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Seifer M; Patty A; Serra I; Li B; Standring DN
Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA
Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559
[TBL] [Abstract][Full Text] [Related]
14. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.
Colledge D; Civitico G; Locarnini S; Shaw T
Antimicrob Agents Chemother; 2000 Mar; 44(3):551-60. PubMed ID: 10681317
[TBL] [Abstract][Full Text] [Related]
15. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Fu L; Liu SH; Cheng YC
Biochem Pharmacol; 1999 Jun; 57(12):1351-9. PubMed ID: 10353255
[TBL] [Abstract][Full Text] [Related]
17. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Murata K; Asano M; Matsumoto A; Sugiyama M; Nishida N; Tanaka E; Inoue T; Sakamoto M; Enomoto N; Shirasaki T; Honda M; Kaneko S; Gatanaga H; Oka S; Kawamura YI; Dohi T; Shuno Y; Yano H; Mizokami M
Gut; 2018 Feb; 67(2):362-371. PubMed ID: 27789659
[TBL] [Abstract][Full Text] [Related]
18. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes.
Köck J; Baumert TF; Delaney WE; Blum HE; von Weizsäcker F
Hepatology; 2003 Dec; 38(6):1410-8. PubMed ID: 14647052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]